key: cord-1029659-0if1lu02 authors: Ghasemnejad-Berenji, Morteza; Pashapour, Sarvin title: Favipiravir and COVID-19: A Simplified Summary date: 2020-11-11 journal: Drug Res (Stuttg) DOI: 10.1055/a-1296-7935 sha: a62e1e000a1088e1475802d73a0858ad03b04bcf doc_id: 1029659 cord_uid: 0if1lu02 A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19. At the end of 2019, novel coronavirus pneumonia (NCP) emerged in Wuhan and had spread rapidly. The pathogen was confirmed new coronavirus, which was officially named coronavirus disease-19 (COVID-19) by the World Health Organization (WHO) [1] . The clinical characteristics of COVID-19 include fever, respiratory symptoms, dyspnea, cough and pneumonia [2] [3] [4] [5] . Currently, there is no specific antiviral treatment for COVID-19. Therefore, identifying drug treatment options as soon as possible is critical for the response to the COVID-19 outbreak [6] . It has been revealed that SARS-CoV-2 has a genome sequence that is 75-80 % identical to that of SARS-CoV, so, the existing treatment favipiravir for SARS and MERS may be helpful for developing COVID-19 therapeutics [7, 8] . Favipiravir, also known as T-705 was being developed in 2002 as an inhibitor of influenza virus replication [9] . The structures of favipiravir shown in ▶Fig. 1. Favipiravir was approved for treatment of novel influenza on February 15, 2020 in China [10] . This drug is currently undergoing clinic trials in treating COVID-19. Favipiravir is a type of RNA-dependent RNA polymerase (RdRp) inhibitor. It is converted by host enzymes to T-705-ribofuranosyl 5′-triphosphate and presumably acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase (▶ Fig. 2 ) or causes lethal mutagenesis upon incorporation into the virus RNA without cytotoxicity to mammalian cells [11] [12] [13] [14] [15] . Besides influenza virus [16] , favipiravir has shown potent antiviral activity against other segmented negative-strand RNA viruses such as arena-and bunyaviruses in vitro and in vivo [17, 18] . In addition, favipiravir has also demonstrated activity against positive-strand RNA viruses such as noro-and flaviviruses [19, 20] . Therefore, favipiravir may have potential antiviral action on SARS-CoV-2, which is an RNA virus. It has been demonstrated that, as a prodrug, favipiravir effectively inhibits the SARSCoV-2 infection in Vero E6 cells (ATCC-1586) [21] . On A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19. February 14, a clinical trial on favipiravir for the treatment of COVID-19 initiated by the Clinical Medical Research Center of the National Infectious Diseases and the Third People's Hospital of Shenzhen achieved promising results. The preliminary results from a total of 80 patients (including the experimental group and the control group) indicated that favipiravir had more potent antiviral action than that of lopinavir/ritonavir. No significant adverse reactions were noted in the favipiravir treatment group, and it had significantly fewer adverse effects than the lopinavir/ritonavir group [7] . Nucleoside analogues in the form of adenine or guanine derivatives target the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. Favipiravir (T-705), a guanine analogue approved for influenza treatment, can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus [16] , and a recent study reported its activity against 2019-novel corona virus. Chinese researchers who studied the effect of favipiravir in vitro (using Vero E6 cell line infected by SARS-CoV-2) found favipiravir to be effective in reducing viral replication (half-maximal effective concentration (EC50) = 61.88 μM, half-cytotoxic concentration (CC50) > 400 μM, selectivity index (SI) > 6.46) [21] . At least 18 different clinical trials for SARS-CoV-2 already registered in the Chinese Clinical Trial Registry (ChiCTR) and the International Clinical Trials Registry Platform (WHO ICTRP) propose to use favipiravir in the treatment of COVID-19 (▶table 1). For example, patients with 2019-nCoV are being recruited in randomized trials to evaluate the efficacy of favipiravir plus interferon-α (ChiC-TR2000029600), favipiravir plus baloxavir marboxil (an approved influenza inhibitor targeting the cap-dependent endonuclease) (ChiCTR2000029544) and favipiravir plus Chloroquine Phosphate (ChiCTR2000030987). In a recent publication, Cai and colleagues found that favipiravir showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance indicate. They investigated the effect of favipiravir versus Lopinavir/Ritonavir on the treatment of COVID-19. They reported that favipiravir was independently associated with faster viral clearance and a higher improvement rate in chest imaging. Their findings suggested that favipiravir has significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance, as compared with Lopinavir/Ritonavir [7] . In the recent study Chen and colleagues compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients on clinical recovery rate of day ▶Fig. 1 Chemical structure of favipiravir (T-705) [16] . ▶Fig. 2 Schematic representation of the activation mechanism of favipiravir (Based on Furuta et al. [22] ). Favipiravir is incorporated into cells and converted to favipiravir ribofuranosyl phosphates by host cell enzymes. The triphosphate form, favipiravir-RTP, inhibits the influenza viral RNA polymerase activity. 7. 120 patients were assigned to favipiravir group (116 assessed) and 120 to arbidol group (120 assessed). In full analysis set (FAS) cohort, for moderate patients with COVID-19, clinical recovery rate of day 7 was 55.86 % in the arbidol group and 71.43 % in the favipiravir group (P = 0.0199). For moderate COVID-19 patients and COVID-19 patients with hypertension and/or diabetes, the latency to fever reduction and cough relief in favipiravir group was significantly shorter than that in arbidol group (both P < 0.001), but there was no statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate (both P > 0.05) [23] . The covid-19 has spread rapidly since its recent identification in patients with severe pneumonia in Wuhan, China. Currently, there is no specific antiviral treatment for COVID-19. Therefore, identifying drug treatment options as soon as possible is critical for the response to the COVID-19 outbreak [10, 24] . One of the potentially quickest ways to find treatment is to test substances already approved or in development for other viral infections. Favipiravir was discovered by chemical modification of a pyrazine analog initially screened by in vitro anti-influenza virus activity in cells [22] . Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase [25] and effective against all subtypes and strains of influenza viruses including ones sensitive or resistant to marketed neuraminidase and M2 inhibitors [26] . Favipiravir demonstrated anti-viral activities against other RNA viruses [27] . These data clearly suggest that favipiravir is a promising drug for the treatment of infections by not only influenza virus but also a wide range of RNA viruses. The research letter, written by a group of Chinese researchers, studied the effect of the influenza antiviral favipiravir in vitro, using Vero E6 cells infected by SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05 demonstrated that favipiravir is effective in reducing viral replication, with half-maximal effective concentration (EC50) 61.88 μM [21] . Furthermore favipiravir, has been tested in clinical trials with Covid-19 patients in China. According to an open-label, non-randomized trial the results showed shorter viral clearance time than the control group that received lopinavir/ritonavir [7] . In addition another multicenter, open-labelled clinical trial reported that in moderate COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment because of the higher clinical recovery rate of day 7 and more effectively reduced incidence of fever, cough besides some manageable antiviral-associated adverse effects [23] . However, data of the above studies indicate the efficacy of favipiravir, we need to wait for more clinically valid evidence to confirm the positive value of this antiviral agent for COVID-19 treatment. Furthermore, the adverse reactions of this drug should be kept in mind. In repeatdose toxicity studies involving dogs, rats, and monkeys, notable findings after administration of oral favipiravir included: adverse effects on hematopoietic tissues such as decreased red blood cell (RBC) production, and increases in liver function parameters such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT) and total bilirubin, and increased vacuolization in hepatocytes. Testis toxicity was also noted [28] . Favipiravir is known to be teratogenic; therefore, administration of favipiravir should be avoided in women if pregnancy is confirmed or suspected [25] and toxicity information regarding favipiravir in humans is not readily available so the Ministry of Health, Labor and Welfare granted conditional marketing approval with strict regulations for its production and clinical use [29] . Favipiravir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge in relation to Covid-19. However more clinical studies are urgently needed to evaluate the efficacy and safety of this antiviral nucleoside for COVID-19 treatment. Author Contributions M Ghasemnejad-Berenji; literature review and writing the manuscript writing the original draft of the review article. S. Pashapour: literature review and revising the review article. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): The epidemic and the challenges World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study Therapeutic options for the 2019 novel coronavirus (2019-nCoV) In vitro and in vivo activities of anti-influenza virus compound T-705 Discovering drugs to treat coronavirus disease 2019 (COVID-19) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro Mechanism of action of T-705 against influenza virus The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset Favipiravir (T-705) inhibits in vitro norovirus replication Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Favipiravir (T-705), a novel viral RNA polymerase inhibitor Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Defining the epidemiology of Covid-19-studies needed Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Favipiravir, an anti-influenza drug against life-threatening RNA virus infections T-705 (favipiravir) inhibition of arenavirus replication in cell culture Favipiravir: a new medication for the Ebola virus disease pandemic The authors declare that they have no conflict of interest.